---
title: "Mizuho Securities Sticks to Their Buy Rating for Atara Biotherapeutics (ATRA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290344061.md"
description: "Mizuho Securities analyst Salim Syed maintained a Buy rating on Atara Biotherapeutics (ATRA) with an $18.00 price target, despite shares closing at $10.07. The firm's consensus for ATRA is a Moderate Buy with a $13.67 target. Syed, who covers the Healthcare sector, has a -1.0% average return and 42.91% success rate."
datetime: "2026-06-21T08:16:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290344061.md)
  - [en](https://longbridge.com/en/news/290344061.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290344061.md)
generator: "portal-rs"
---

# Mizuho Securities Sticks to Their Buy Rating for Atara Biotherapeutics (ATRA)

Mizuho Securities analyst Salim Syed maintained a Buy rating on Atara Biotherapeutics on June 18 and set a price target of $18.00. The company’s shares closed last Thursday at $10.07.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

According to TipRanks, Syed is an analyst with an average return of -1.0% and a 42.91% success rate. Syed covers the Healthcare sector, focusing on stocks such as Century Therapeutics, Atara Biotherapeutics, and Assembly Biosciences.

Atara Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $13.67.

### Related Stocks

- [ATRA.US](https://longbridge.com/en/quote/ATRA.US.md)
- [8411.JP](https://longbridge.com/en/quote/8411.JP.md)
- [MFG.US](https://longbridge.com/en/quote/MFG.US.md)
- [IPSC.US](https://longbridge.com/en/quote/IPSC.US.md)
- [ASMB.US](https://longbridge.com/en/quote/ASMB.US.md)

## Related News & Research

- [Morgans Remains a Buy on EchoIQ Limited (EIQ)](https://longbridge.com/en/news/297720502.md)
- [09:01 ETHealthcare Is Moving Into the Home. Home Accessibility Now Has a Validated Score.](https://longbridge.com/en/news/297656740.md)
- [Cellectis to present at Baird Global Healthcare Conference](https://longbridge.com/en/news/297695285.md)
- [SoundHound AI (SOUN) On Healthcare Deal Momentum And The Case For A Higher Valuation](https://longbridge.com/en/news/297694466.md)
- [Akebia Therapeutics holds investor meetings at Wells Fargo Healthcare Conference](https://longbridge.com/en/news/297649009.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**